BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 16419571)

  • 1. [Migraine and irritable bowel syndrome].
    Mulak A; Paradowski L
    Neurol Neurochir Pol; 2005; 39(4 Suppl 1):S55-60. PubMed ID: 16419571
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High prevalence of nausea in children with pain-associated functional gastrointestinal disorders: are Rome criteria applicable?
    Kovacic K; Williams S; Li BU; Chelimsky G; Miranda A
    J Pediatr Gastroenterol Nutr; 2013 Sep; 57(3):311-5. PubMed ID: 23591912
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Visceral hypersensitivity in irritable bowel syndrome.
    Kanazawa M; Hongo M; Fukudo S
    J Gastroenterol Hepatol; 2011 Apr; 26 Suppl 3():119-21. PubMed ID: 21443723
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Role of serotonin in the pathophysiology of the irritable bowel syndrome].
    Moskwa A; Boznańska P
    Wiad Lek; 2007; 60(7-8):371-6. PubMed ID: 18175558
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Abdominal pain in Irritable Bowel Syndrome: a review of putative psychological, neural and neuro-immune mechanisms.
    Elsenbruch S
    Brain Behav Immun; 2011 Mar; 25(3):386-94. PubMed ID: 21094682
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of serotonin in the pathophysiology of the irritable bowel syndrome.
    Crowell MD
    Br J Pharmacol; 2004 Apr; 141(8):1285-93. PubMed ID: 15100164
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The brain-gut axis in irritable bowel syndrome--clinical aspects.
    Mach T
    Med Sci Monit; 2004 Jun; 10(6):RA125-31. PubMed ID: 15173682
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Eluxadoline benefits patients with irritable bowel syndrome with diarrhea in a phase 2 study.
    Dove LS; Lembo A; Randall CW; Fogel R; Andrae D; Davenport JM; McIntyre G; Almenoff JS; Covington PS
    Gastroenterology; 2013 Aug; 145(2):329-38.e1. PubMed ID: 23583433
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence of post-infectious irritable bowel syndrome and functional intestinal disorders following a water-borne viral gastroenteritis outbreak.
    Zanini B; Ricci C; Bandera F; Caselani F; Magni A; Laronga AM; Lanzini A;
    Am J Gastroenterol; 2012 Jun; 107(6):891-9. PubMed ID: 22525306
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intestinal serotonin release, sensory neuron activation, and abdominal pain in irritable bowel syndrome.
    Cremon C; Carini G; Wang B; Vasina V; Cogliandro RF; De Giorgio R; Stanghellini V; Grundy D; Tonini M; De Ponti F; Corinaldesi R; Barbara G
    Am J Gastroenterol; 2011 Jul; 106(7):1290-8. PubMed ID: 21427712
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rationale for using serotonergic agents to treat irritable bowel syndrome.
    Baker DE
    Am J Health Syst Pharm; 2005 Apr; 62(7):700-11; quiz 712-3. PubMed ID: 15790796
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic and therapeutic strategies in the irritable bowel syndrome.
    Cremonini F; Talley NJ
    Minerva Med; 2004 Oct; 95(5):427-41. PubMed ID: 15467518
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intrarectal lidocaine is an effective treatment for abdominal pain associated with diarrhea-predominant irritable bowel syndrome.
    Verne GN; Sen A; Price DD
    J Pain; 2005 Aug; 6(8):493-6. PubMed ID: 16084463
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Irritable bowel syndrome: recent and novel therapeutic approaches.
    Andresen V; Camilleri M
    Drugs; 2006; 66(8):1073-88. PubMed ID: 16789793
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antidepressants in the treatment of irritable bowel syndrome and visceral pain syndromes.
    Crowell MD; Jones MP; Harris LA; Dineen TN; Schettler VA; Olden KW
    Curr Opin Investig Drugs; 2004 Jul; 5(7):736-42. PubMed ID: 15298070
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emerging pharmacological therapies for the irritable bowel syndrome.
    Maneerattanaporn M; Chang L; Chey WD
    Gastroenterol Clin North Am; 2011 Mar; 40(1):223-43. PubMed ID: 21333909
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The use of psychotropic drugs in irritable bowel syndrome.
    Dekel R; Drossman DA; Sperber AD
    Expert Opin Investig Drugs; 2013 Mar; 22(3):329-39. PubMed ID: 23316916
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression and role of 5-HT7 receptor in brain and intestine in rats with irritable bowel syndrome.
    Zou BC; Dong L; Wang Y; Wang SH; Cao MB
    Chin Med J (Engl); 2007 Dec; 120(23):2069-74. PubMed ID: 18167178
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent advances in understanding the role of serotonin in gastrointestinal motility in functional bowel disorders: alterations in 5-HT signalling and metabolism in human disease.
    Spiller R
    Neurogastroenterol Motil; 2007 Aug; 19 Suppl 2():25-31. PubMed ID: 17620085
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use of novel promotility and prosecretory agents for the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation.
    Gale JD
    Adv Ther; 2009 May; 26(5):519-30. PubMed ID: 19444393
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.